2010 in oncology

The approvals rows on treatment records: region, year and indication.

• 2010Bendamustine approved in EU

  CLL, indolent NHL, multiple myeloma (national approvals)

• 2010Cabazitaxel approved in US

  mCRPC after docetaxel

• 2010Denosumab approved in US

  Prevention of skeletal-related events in bone metastases from solid tumours (Xgeva); postmenopausal osteoporosis and treatment-induced bone loss (Prolia)

• 2010Eribulin approved in US

  Metastatic breast cancer after ≥2 regimens including an anthracycline and a taxane

• 2010HER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH) approved in US

  HER2 testing extended to gastric and GEJ adenocarcinoma with trastuzumab (ToGA)

• 2010Hexaminolevulinate approved in US

  Cystoscopic detection of non-muscle-invasive papillary bladder cancer, with blue-light cystoscopy

• 2010Lapatinib approved in US

  HR+/HER2+ metastatic breast cancer with letrozole

• 2010Nilotinib approved in US

  Newly diagnosed Ph+ CML chronic phase

• 2010Ofatumumab approved in EU

  CLL refractory to fludarabine and alemtuzumab (conditional; authorisation since withdrawn)

• 2010Rituximab approved in US

  CLL with fludarabine and cyclophosphamide

• 2010Sipuleucel-T approved in US

  Asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer

• 2010Thiotepa approved in EU

  Conditioning before haematopoietic progenitor cell transplantation for haematological diseases and solid tumours (Tepadina)

• 2010Tocilizumab approved in US

  Rheumatoid arthritis (first approval)

• 2010Trastuzumab approved in US

  HER2+ gastric cancer

The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.

• 21 June 2010Gemtuzumab ozogamicin: withdrawal (US)

  Voluntary withdrawal after confirmatory trial showed no benefit and excess deaths

• 20 October 2010Trastuzumab: approval (US)

  HER2+ metastatic gastric cancer (ToGA)

The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.

• 2010Biologics Price Competition and Innovation Act 2010

  United States, statute.

• 2010Biosimilar

  United States, guidance.

The year reported on trial records, with the headline result the record gives.

• 2010A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) reported
  Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)Romidepsin
• 2010ABC-02 reported

  OS 11.7 vs 8.1 months, HR 0.64.

  Biliary tract cancer (cholangiocarcinoma)Gallbladder cancerBiliary tract cancer (all types)Gemcitabine + cisplatin
• 2010ALL R3 (UKALLR3) reported

  Three-year progression-free survival 64.6 percent with mitoxantrone against 35.9 percent with idarubicin, and overall survival 69.0 against 45.2 percent; the randomisation was stop...

  Relapsed and refractory acute lymphoblastic leukaemia in childrenAcute lymphoblastic leukaemiaLeukaemia (all types)Mitoxantrone
• 2010COG ANBL0032 reported

  2-year EFS 66% vs 46%; OS 86% vs 75%.

  Neuroblastoma (paediatric)High-risk neuroblastomaDinutuximab (ch14.18) / dinutuximab betaIsotretinoin
• 2010Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing...
  HR-positive / HER2-negative breast cancerFulvestrant
• 2010DASISION reported

  Dasatinib produced higher confirmed complete cytogenetic and major molecular response rates at 12 months than imatinib, with no difference in five-year overall survival.

  Chronic myeloid leukaemia, chronic phaseChronic myeloid leukaemia (CML)DasatinibImatinib
• 2010EORTC 22863 reported

  Ten-year overall survival 58.1 against 39.8 percent (hazard ratio 0.60, 95 percent confidence interval 0.45 to 0.80) and prostate cancer mortality 10.3 against 30.4 percent (0.38...

  Prostate cancerLocalised prostate cancer, high and very high riskGoserelin / leuprolide (ovarian function suppression)
• 2010ESPAC-3 reported

  Median overall survival 23.0 months with fluorouracil plus folinic acid against 23.6 months with gemcitabine (hazard ratio 0.94, p 0.39); treatment-related serious adverse events 1...

  Resectable pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaAmpullary cancer (ampulla of Vater)Fluorouracil (5-FU)
• 2010IMPACT (sipuleucel-T) reported

  Median overall survival 25.8 against 21.7 months (hazard ratio 0.78, 95 percent confidence interval 0.61 to 0.98, p=0.03) with no difference in time to objective disease progressio...

  Prostate cancerMetastatic castration-resistant prostate cancerSipuleucel-T
• 2010NSABP B-32 reported

  Eight-year overall survival 90.3 percent with sentinel node biopsy alone against 91.8 percent with added clearance (hazard ratio 1.20, 0.96 to 1.50, p=0.12); regional recurrence 14...

  Breast cancer (all types)HR-positive / HER2-negative breast cancerHER2-positive breast cancerTriple-negative breast cancer (TNBC)
• 2010PORTEC-2 reported

  Vaginal brachytherapy gave similar vaginal control and survival to external beam radiotherapy with less gastrointestinal toxicity.

  Endometrial cancer with no specific molecular profilePOLE-ultramutated endometrial cancerEndometrial cancer
• 2010RTOG 0129 (HPV analysis) reported

  3-year OS 82.4% (HPV+) vs 57.1% (HPV-).

  Head and neck squamous cell carcinomaHPV-positive oropharyngeal cancer
• 2010ToGA reported

  OS 13.8 vs 11.1 months, HR 0.74.

  Gastric & gastro-oesophageal junction cancerHER2-positive gastric cancerTrastuzumab
• 2010TROPIC reported

  Median survival 15.1 against 12.7 months (hazard ratio 0.70, 95 percent confidence interval 0.59 to 0.83); grade 3 or higher neutropenia in 82 percent and febrile neutropenia in 8...

  Prostate cancerMetastatic castration-resistant prostate cancerCabazitaxelMitoxantrone
• 2010UK Flexible Sigmoidoscopy Screening Trial reported

  Colorectal cancer incidence 23 percent lower and mortality 31 percent lower in those invited to a single flexible sigmoidoscopy (33 percent and 43 percent among attenders); the 17-...

  Colorectal cancer

The publication year on key paper records.

• 2010A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

  Sharma SV, Lee DY, Li B, et al. Cell.

• 2010A3961: outcome after reduced chemotherapy for intermediate-risk neuroblastoma

  Baker DL, Schmidt ML, Cohn SL, et al. New England Journal of Medicine.

• 2010ABC-02: cisplatin plus gemcitabine versus gemcitabine alone for biliary tract cancer

  Valle J, Wasan H, Palmer DH, et al. New England Journal of Medicine.

• 2010ALL R3: mitoxantrone versus idarubicin in first relapse of childhood acute lymphoblastic leukaemia

  Parker C, Waters R, Leighton C, et al. The Lancet.

• 2010American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone re...

  Hammond ME, Hayes DF, Dowsett M, et al. Journal of Clinical Oncology.

• 2010Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

  Kwak EL, Bang YJ, Camidge DR, et al. New England Journal of Medicine.

• 2010Angiosarcoma (review)

  Young RJ, Brown NJ, Reed MW, et al. The Lancet Oncology.

• 2010Anti-GD2 antibody with GM-CSF, interleukin-2 and isotretinoin for high-risk neuroblastoma (COG ANBL0032)

  Yu AL, Gilman AL, Ozkaynak MF, et al. New England Journal of Medicine.

• 2010ARID1A mutations in endometriosis-associated ovarian carcinomas

  Wiegand KC, Shah SP, Al-Agha OM, et al. New England Journal of Medicine.

• 2010Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

  Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Journal of Clinical Oncology.

• 2010Cancer as a metabolic disease

  Seyfried TN, Shelton LM. Nutrition & metabolism.

• 2010Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial

  Lu C, Lee JJ, Komaki R, et al. JNCI: Journal of the National Cancer Institute.

• 2010Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumours

  Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Journal of Clinical Oncology.

• 2010Distant metastasis occurs late during the genetic evolution of pancreatic cancer

  Yachida S, Jones S, Bozic I, et al. Nature.

• 2010Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

  Rustin GJ, van der Burg ME, Griffin CL, et al. The Lancet.

• 2010ESPAC-3: adjuvant fluorouracil plus folinic acid versus gemcitabine after pancreatic cancer resection

  Neoptolemos JP, Stocken DD, Bassi C, et al. JAMA.

• 2010Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer

  Weiss J, Sos ML, Seidel D, et al. Science Translational Medicine.

• 2010Frequent mutations of the chromatin remodelling gene ARID1A in ovarian clear cell carcinoma

  Jones S, Wang TL, Shih IeM, et al. Science.

• 2010Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

  Maemondo M, Inoue A, Kobayashi K, et al. New England Journal of Medicine.

• 2010GHSG HD10: reduced treatment intensity in early-stage favourable Hodgkin lymphoma

  Engert A, Plütschow A, Eich HT, et al. New England Journal of Medicine.

• 2010Grivennikov, Greten and Karin 2010: immunity, inflammation and cancer

  Grivennikov SI, Greten FR, Karin M. Cell.

• 2010Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma

  Hodi FS, O'Day SJ, McDermott DF, et al. New England Journal of Medicine.

• 2010Human papillomavirus and survival of patients with oropharyngeal cancer (RTOG 0129)

  Ang KK, Harris J, Wheeler R, et al. New England Journal of Medicine.

• 2010Imatinib in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase 2 trials (EORTC 62027 and SWOG S0345)

  Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Journal of Clinical Oncology.

• 2010Integrative genomic profiling of human prostate cancer

  Taylor BS, Schultz N, Hieronymus H, et al. Cancer Cell.

• 2010Jemal 2010: Cancer statistics, 2010

  Jemal A, Siegel R, Xu J, Ward E. CA: A Cancer Journal for Clinicians.

• 2010Lemmon and Schlessinger 2010: cell signalling by receptor tyrosine kinases

  Lemmon MA, Schlessinger J. Cell.

• 2010Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial

  Annema JT, van Meerbeeck JP, Rintoul RC, et al. JAMA.

• 2010Multidisciplinary team working in cancer: what is the evidence?

  Taylor C, Munro AJ, Glynne-Jones R, et al. BMJ.

• 2010Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study

  Issels RD, Lindner LH, Verweij J, et al. The Lancet Oncology.

• 2010Neoadjuvant paclitaxel, ifosfamide and cisplatin (TIP) for penile cancer with bulky lymph node metastases

  Pagliaro LC, Williams DL, Daliani D, et al. Journal of Clinical Oncology.

• 2010Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

  Tefferi A. Leukemia.

• 2010Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial

  Atkin WS, Edwards R, Kralj-Hans I, et al. The Lancet.

• 2010Overdiagnosis in cancer

  Welch HG, Black WC. JNCI: Journal of the National Cancer Institute.

• 2010Pancreatic cancer

  Hidalgo M. New England Journal of Medicine.

• 2010Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma

  Royal RE, Levy C, Turner K, et al. Journal of Immunotherapy.

• 2010PORTEC-2: vaginal brachytherapy versus pelvic external beam radiotherapy for high-intermediate-risk endometrial cancer

  Nout RA, Smit VT, Putter H, et al. The Lancet.

• 2010Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial

  Roth AD, Tejpar S, Delorenzi M, et al. Journal of Clinical Oncology.

• 2010PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers

  Domchek SM, Friebel TM, Singer CF, et al. JAMA.

• 2010Quality indicators for colonoscopy and the risk of interval cancer

  Kaminski MF, Regula J, Kraszewska E, et al. New England Journal of Medicine.

• 2010Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues

  Bentzen SM, Constine LS, Deasy JO, et al. International Journal of Radiation Oncology, Biology, Physics.

• 2010Recurrent BRAF mutations in Langerhans cell histiocytosis

  Badalian-Very G, Vergilio JA, Degar BA, et al. Blood.

• 2010Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma

  Sparano JA, Lee JY, Kaplan LD, et al. Blood.

• 2010Selective inhibition of BET bromodomains

  Filippakopoulos P, Qi J, Picaud S, et al. Nature.

• 2010Sipuleucel-T immunotherapy for castration-resistant prostate cancer

  Kantoff PW, Higano CS, Shore ND, et al. New England Journal of Medicine.

• 2010Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

  Barretina J, Taylor BS, Banerji S, et al. Nature Genetics.

• 2010Temel: early palliative care alongside chemotherapy improved quality of life, mood and survival in lung cancer

  Temel JS, Greer JA, Muzikansky A, et al. New England Journal of Medicine.

• 2010ToGA (Bang 2010): trastuzumab with chemotherapy for HER2-positive advanced gastric cancer

  Bang YJ, Van Cutsem E, Feyereislova A, et al. The Lancet.

• 2010TROPIC: prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel

  de Bono JS, Oudard S, Ozguroglu M, et al. The Lancet.

• 2010What are the hallmarks of cancer?

  Lazebnik Y. Nature Reviews Cancer.

The history entries editors wrote on cancer records: the dated turning points of each disease.

• 2010A second line opens

  Prostate cancer. TROPIC gave cabazitaxel after docetaxel: 15.1 against 12.7 months, with grade 3 or higher neutropenia in 82 percent.

  TROPIC: prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel
• 2010A3961: biology-based reduction to four or eight cycles gives 96 percent three-year survival

  Intermediate-risk neuroblastoma

  CarboplatinEtoposideCyclophosphamideDoxorubicin
• 2010ABC-02: gemcitabine plus cisplatin becomes the standard for advanced biliary cancer

  Intrahepatic cholangiocarcinoma

  ABC-02Gemcitabine + cisplatin
• 2010ABC-02: gemcitabine plus cisplatin standard for advanced biliary cancer

  Extrahepatic cholangiocarcinoma (perihilar and distal)

  ABC-02Gemcitabine + cisplatin
• 2010ABC-02: gemcitabine-cisplatin becomes standard

  Biliary tract cancer (cholangiocarcinoma)

  ABC-02Gemcitabine + cisplatin
• 2010ABC-02: gemcitabine-cisplatin becomes standard

  Biliary tract cancer (all types)

  ABC-02
• 2010AMC 034: rituximab with EPOCH is safe and effective

  HIV-associated (AIDS-related) lymphomas. Sparano and colleagues (Blood 2010) establish concurrent R-EPOCH.

  RituximabEtoposide
• 2010ANBL0032: anti-GD2 antibody with GM-CSF and interleukin-2 raises two-year event-free survival from 46 to 66 percent

  High-risk neuroblastoma

  COG ANBL0032Dinutuximab (ch14.18) / dinutuximab beta
• 2010ANBL0032: anti-GD2 immunotherapy raises survival ~20 points (NEJM)

  Neuroblastoma (paediatric)

  COG ANBL0032Dinutuximab (ch14.18) / dinutuximab beta
• 2010Ang shows HPV status is the dominant prognostic factor

  Oropharyngeal cancer (tonsil and base of tongue). RTOG 0129 analysis: three-year survival 82 versus 57 percent.

• 2010Anti-GD2 (ch14.18) improves EFS

  Neuroblastoma (paediatric)

• 2010ARID1A mutations discovered in clear cell carcinoma

  Clear cell ovarian cancer

• 2010BAP1 loss drives metastasis (Harbour, Science)

  Uveal melanoma

• 2010BET inhibitor JQ1 induces differentiation of NUT carcinoma cells

  NUT carcinoma (midline carcinoma with NUTM1 rearrangement). Filippakopoulos and colleagues, Nature: proof of concept for BET inhibition.

• 2010BRAF V600E discovered in Langerhans cell histiocytosis

  Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)

  BRAFRAS / RAF / MEK / ERK (MAPK)
• 2010BRAF V600E discovered in LCH

  Langerhans cell histiocytosis (LCH). Badalian-Very and colleagues (Blood) show LCH is a clonal MAPK-driven neoplasm.

  BRAFRAS / RAF / MEK / ERK (MAPK)
• 2010BRAF V600E found in over half of lesions

  Single-system Langerhans cell histiocytosis (bone, skin or one other organ)

  BRAFRAS / RAF / MEK / ERK (MAPK)
• 2010Cabazitaxel and sipuleucel-T approved

  Metastatic castration-resistant prostate cancer

  CabazitaxelSipuleucel-T
• 2010Claudin-low described as a breast cancer subtype

  Triple-negative breast cancer (TNBC). Mostly triple-negative tumours with epithelial-to-mesenchymal transition and stem-cell features (Prat, Breast Cancer Research); re-defined as...

  Claudin-low breast cancer
• 2010CLL8: fludarabine-cyclophosphamide-rituximab lengthens life, the first regimen to do so

  Chronic lymphocytic leukaemia, first treatment

  FludarabineRituximab
• 2010Copy-number burden as a risk measure

  Prostate cancer. Profiling 218 tumours on three platforms identifies NCOA2 as an oncogene in 11% and shows that counting copy-number changes separates high- from low-risk disease b...

  Integrative genomic profiling of human prostate cancerNCOA2
• 2010Crizotinib response in ALK-positive IMT

  Inflammatory myofibroblastic tumour (IMT). Butrynski and colleagues, NEJM case report.

• 2010Cystic duct cancer joins gallbladder staging

  Gallbladder cancer. The AJCC 7th edition stages carcinoma of the cystic duct with gallbladder cancer.

  Cystic duct carcinoma
• 2010Drug-eluting bead TACE (PRECISION V) matches conventional TACE with less toxicity

  Intermediate hepatocellular carcinoma (BCLC B)

  Transarterial chemoembolisation (TACE)
• 2010Early palliative care trial

  Metastatic cancer (cancer that has spread). Temel and colleagues randomise newly diagnosed metastatic lung cancer patients to early palliative care with standard oncology: better q...

  Early integrated palliative care
• 2010Endoscopic endonasal resection shown equivalent to craniofacial resection in series

  Esthesioneuroblastoma (olfactory neuroblastoma)

• 2010EORTC 62961: regional hyperthermia with chemotherapy improves survival in high-risk STS

  Sarcomas (soft tissue, bone, GIST)

  Hyperthermia
• 2010FCR: first regimen to improve survival

  Chronic lymphocytic leukaemia. CLL8 shows fludarabine-cyclophosphamide-rituximab beats FC on OS; rituximab approved in CLL.

  Rituximab
• 2010Fusion-negative alveolar RMS behaves like embryonal (Williamson, JCO)

  Rhabdomyosarcoma. Leads to fusion-based risk stratification.

• 2010G-PCNSL-SG-1: omitting WBRT does not shorten survival

  Primary CNS lymphoma. Sets the stage for radiation-free strategies.

• 2010Gemcitabine and cisplatin become the biliary standard

  Gallbladder cancer. ABC-02 (NEJM 2010) in a mixed biliary population including gallbladder cancer.

  ABC-02Gemcitabine + cisplatin
• 2010Gene-expression tissue-of-origin classifiers reach clinical use

  Cancer of unknown primary, favourable subsets

• 2010GHSG HD10: two ABVD and 20 Gy suffice for early favourable disease

  Early-stage classical Hodgkin lymphoma (stage I to II)

  ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)IMRT / IGRT (modern external beam)
• 2010Intensity-modulated radiotherapy shown to reduce xerostomia and improve control

  Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)

  IMRT / IGRT (modern external beam)
• 2010Ipilimumab is the first drug to extend survival in metastatic melanoma

  Melanoma. Hodi et al., NEJM.

  Ipilimumab
• 2010Ipilimumab is the first drug to lengthen survival in advanced melanoma

  Advanced melanoma (unresectable stage III and stage IV)

  Ipilimumab
• 2010ITMIG founded; global retrospective database

  Thymoma and thymic carcinoma

• 2010Johns Hopkins series: 10 percent of resected adenocarcinomas are IPMN-associated, five-year survival 42 against 19 percent

  Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma)

  Whipple procedure (pancreaticoduodenectomy)
• 2010Kuma Hospital reports safe observation of microcarcinomas

  Papillary thyroid cancer. Ito and Miyauchi's series of over a thousand patients.

• 2010Mammary analogue secretory carcinoma with ETV6-NTRK3 described (Skálová)

  Salivary gland cancers

  NTRK
• 2010MD Anderson phase 2: neoadjuvant TIP produces responses in half of men with bulky nodes

  Node-positive and metastatic penile cancer

  Paclitaxel / nab-paclitaxelIfosfamideCisplatin
• 2010Metastasis shown to occur late

  Pancreatic ductal adenocarcinoma. A decade from the initiating mutation to the founder clone and five more years to metastatic ability: the quantitative case for early detection.

  Distant metastasis occurs late during the genetic evolution of pancreatic cancer
• 2010MYC amplification found in radiation-associated and lymphoedema angiosarcoma

  Angiosarcoma

• 2010NSABP B-32: the sentinel node replaces axillary clearance

  Breast cancer (all types). 5,611 women; eight-year overall survival 90.3 against 91.8 percent, and in ALMANAC lymphoedema at a year fell from 13 to 5 percent.

  NSABP B-32ALMANAC (Axillary Lymphatic Mapping Against Nodal Axillary Clearance)
• 2010One flexible sigmoidoscopy, and the adenoma detection rate

  Colorectal cancer. Atkin, 170,432 people: incidence down 23 percent and mortality 31 percent, still holding at 17 years.

  Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trialLong term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-upQuality indicators for colonoscopy and the risk of interval cancer
• 2010Pooled EORTC 62027 and SWOG S0345: imatinib responses in about half of patients (JCO)

  Dermatofibrosarcoma protuberans

  Imatinib
• 2010PORTEC-2: vaginal brachytherapy replaces pelvic radiation for intermediate risk

  Endometrial cancer

  Brachytherapy
• 2010PORTEC-2: vaginal brachytherapy replaces pelvic radiotherapy for high-intermediate risk

  Endometrial cancer with no specific molecular profile

  Brachytherapy
• 2010RTOG 0129 analysis: HPV status is the strongest prognostic factor

  HPV-positive oropharyngeal cancer

  RTOG 0129 (HPV analysis)
• 2010RTOG 0129: HPV status is the dominant prognostic factor

  Head and neck squamous cell carcinoma

  RTOG 0129 (HPV analysis)HPV-positive (p16) head and neck cancer
• 2010Sirolimus responses reported in malignant PEComa with TSC loss

  Perivascular epithelioid cell tumour (PEComa)

  mTOR
• 2010The first tractable target in squamous lung cancer

  Non-small-cell lung cancer. Focal FGFR1 amplification in 22% of squamous cell lung cancers, with selective killing of amplified cell lines by FGFR inhibition.

  Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancerFGFR1
• 2010The serrated pathway is accepted as a second route to cancer

  Colorectal cancer. Sessile serrated lesions and traditional serrated adenomas, with promoter methylation and BRAF or KRAS mutation, account for about 30 percent of colorectal carci...

  Serrated pathwayPolyp types in the bowel
• 2010TIP neoadjuvant chemotherapy

  Penile cancer. Pagliaro and colleagues (JCO 2010) report responses and resectability in bulky nodal disease.

  Paclitaxel / nab-paclitaxelCisplatinIfosfamide
• 2010ToGA includes GEJ adenocarcinoma: trastuzumab for HER2-positive disease

  Oesophageal cancer

  ToGATrastuzumab
• 2010ToGA: trastuzumab for HER2-positive gastro-oesophageal cancer

  Oesophageal and junctional adenocarcinoma

  Trastuzumab
• 2010ToGA: trastuzumab in HER2+ gastric cancer

  Gastric & gastro-oesophageal junction cancer

  Trastuzumab
• 2010ToGA: trastuzumab plus chemotherapy extends survival in HER2-positive gastric cancer

  HER2-positive gastric cancer

  ToGATrastuzumab
• 2010ToGA: trastuzumab, the first targeted therapy in gastric cancer

  Gastric & gastro-oesophageal junction cancer

  ToGATrastuzumab
• 2010UKALLR3: mitoxantrone reinduction nearly doubles progression-free survival in relapsed childhood ALL

  Relapsed and refractory acute lymphoblastic leukaemia in children

  Mitoxantrone
• 2010WHO classification separates appendiceal mucinous neoplasms from adenocarcinoma

  Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)

• 2010WHO classification separates poorly differentiated neuroendocrine carcinoma from neuroendocrine tumours

  Extrapulmonary neuroendocrine carcinoma

  Neuroendocrine tumour grade (Ki-67) and WHO classification

The since year on technology records: first use in humans or first approval, as the record states it.

• 2010Adaptive radiotherapy (online replanning)

  First use in humans or first approval, as the technology record states it.

• 2010Dendritic cell vaccines

  First use in humans or first approval, as the technology record states it.

• 2010Hand-held and point-of-care ultrasound

  First use in humans or first approval, as the technology record states it.

• 2010HER2 PET

  First use in humans or first approval, as the technology record states it.

• 2010Percutaneous hepatic perfusion (chemosaturation)

  First use in humans or first approval, as the technology record states it.

• 2010PET/MRI

  First use in humans or first approval, as the technology record states it.

• 2010Prehabilitation before cancer surgery

  First use in humans or first approval, as the technology record states it.

• 2010Surface-guided radiotherapy (SGRT)

  First use in humans or first approval, as the technology record states it.

The founded year on company records.

• 2010AbClon founded

  Seoul

• 2010Blaze Bioscience founded

  Seattle, WA

• 2010Carthera founded

  Lyon

• 2010Fondazione Italiana Linfomi founded

  Alessandria

• 2010Longwood Fund founded

  Boston, MA

• 2010On Target Laboratories founded

  West Lafayette, IN

• 2010Rakuten Medical founded

  San Diego

• 2010Sichuan Huiyu Pharmaceutical founded

  Neijiang, Sichuan

• 2010Wuhan YZY Biopharma founded

  Wuhan

• 2010WuXi Biologics founded

  Wuxi / Shanghai

The founded year on journal records.

• 2010Analytical cellular pathology (Amsterdam) founded

  Wiley (formerly Hindawi)

• 2010Cancer cytopathology founded

  Wiley

• 2010Clinical lymphoma, myeloma & leukemia founded

  Elsevier

• 2010Journal of cachexia, sarcopenia and muscle founded

  Wiley

• 2010Journal of gastric cancer founded

  Korean Gastric Cancer Association

• 2010Journal of geriatric oncology founded

  Elsevier

• 2010Nature Communications founded

  Springer Nature

• 2010Thoracic cancer founded

  Wiley

The selected publications each biography lists, which is a reading of that person rather than a reading of the year.

• 201089Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo

  Journal of Nuclear Medicine

• 2010Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection (ESPAC-3)

  JAMA

• 2010Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia

  Blood

• 2010Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

  New England Journal of Medicine

• 2010Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model

  Genes & Development

• 2010Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia

  Nature

• 2010Catumaxomab – trifunctional anti-EpCAM antibody used to treat malignant ascites

  Expert Opinion on Biological Therapy

• 2010Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099

  Journal of Clinical Oncology

• 2010Childhood cancer trends in a western Canadian province: A population‐based 22‐year retrospective study

  Pediatric Blood & Cancer

• 2010Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer (ABC-02)

  NEJM

• 2010Concurrent radiochemotherapy in advanced hypopharyngeal cancer

  Radiat Oncol

• 2010Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies

  Am J Hum Genet

• 2010Development of monocytes, macrophages, and dendritic cells

  Science

• 2010DNMT3A mutations in acute myeloid leukemia

  New England Journal of Medicine

• 2010Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients

  Journal of Clinical Oncology

• 2010Early palliative care for patients with metastatic non-small-cell lung cancer

  NEJM

• 2010Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiother...

  Annals of Oncology

• 2010Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study

  Oncologist

• 2010Evaluating Overall Survival and Competing Risks of Death in Patients With Localized Renal Cell Carcinoma Using a Comprehensive Nomogram

  Journal of Clinical Oncology

• 2010FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0

  European Journal of Nuclear Medicine and Molecular Imaging

• 2010First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX)

  Lancet

• 2010Genetic variegation of clonal architecture and propagating cells in leukaemia

  Nature

• 2010Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

  The Lancet

• 2010Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-w...

  Blood

• 2010Improved survival with ipilimumab in patients with metastatic melanoma

  New England Journal of Medicine

• 2010Improving outcomes for patients with diffuse large B-cell lymphoma

  CA: a Cancer Journal for Clinicians

• 2010Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype

  Journal of Clinical Oncology

• 2010Inhibition of mutated, activated BRAF in metastatic melanoma

  New England Journal of Medicine

• 2010Large animal models of hematopoietic stem cell gene therapy

  Gene Therapy

• 2010Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label...

  Lancet Oncology

• 2010Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy

  Breast Cancer Research and Treatment

• 2010Long-term results of hypofractionated radiation therapy for breast cancer

  NEJM

• 2010Major and minor salivary gland tumors

  Critical Reviews in Oncology/Hematology

• 2010Management of non-Hodgkin lymphomas arising at extranodal sites

  Therapeutische Umschau

• 2010Metastatic behavior of breast cancer subtypes

  Journal of Clinical Oncology

• 2010Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL inte...

  Blood

• 2010mTOR signaling and drug development in cancer

  Nature Reviews Clinical Oncology

• 2010Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer (EORTC 55971)

  NEJM

• 2010Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia (ENESTnd)

  NEJM

• 2010Outcomes of Endoscopic Submucosal Dissection Versus Endoscopic Mucosal Resection in Management of Superficial Squamous Esophageal Neoplasms Outside Japan

  Journal of Clinical Gastroenterology

• 2010Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials

  Journal of Clinical Oncology

• 2010Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: A population‐based study

  International Journal of Cancer

• 2010Preoperative MRI and surgical management in patients with nonpalpable breast cancer: The MONET – Randomised controlled trial

  European Journal of Cancer

• 2010Probing the probes: fitness factors for small molecule tools

  Chemistry & Biology

• 2010Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on c...

  Lancet Oncology

• 2010Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Pr...

  JCO

• 2010Recent advances in neuroblastoma

  NEJM

• 2010Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma (HD10)

  NEJM

• 2010Selenium: a double-edged sword for defense and offence in cancer

  Arch Toxicol

• 2010Stereotactic body radiation therapy for inoperable early stage lung cancer (RTOG 0236)

  JAMA

• 2010Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial

  Lancet Oncology

• 2010Telomeres and telomerase in cancer

  Carcinogenesis

• 2010Trastuzumab in combination with chemotherapy versus chemotherapy alone for HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA)

  Lancet

• 2010Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group (RANO)

  JCO

• 2010Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2)

  Lancet

• 2010Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised...

  Lancet Oncology

• 2010Vitamin D and cancer

  Journal of Steroid Biochemistry and Molecular Biology